Q4 2017 13F Holders as of 31 Dec 2017
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
37,285,807
-
Share change
-
-1,543,764
-
Total reported value
-
$1,409,999,138
-
Put/Call ratio
-
421%
-
Price per share
-
$37.82
-
Number of holders
-
123
-
Value change
-
-$55,448,638
-
Number of buys
-
66
-
Number of sells
-
50
Institutional Holders of AIMMUNE THERAPEUTICS INC - COM (AIMT) as of Q4 2017
As of 31 Dec 2017,
AIMMUNE THERAPEUTICS INC - COM (AIMT) was held by
123 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
37,285,807 shares.
The largest 10 holders included
Foresite Capital Management II, LLC, BlackRock Inc., Vanguard Group Inc, FMR LLC, PRICE T ROWE ASSOCIATES INC /MD/, Aisling Capital LLC, EAGLE ASSET MANAGEMENT INC, CARILLON TOWER ADVISERS, INC., ALLIANCEBERNSTEIN L.P., and ADAGE CAPITAL PARTNERS GP, L.L.C..
This page lists
123
institutional shareholders reporting positions in this security
for the Q4 2017 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.